# Kolltan Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kolltan-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: New Haven, US
- Total disclosed funding: $131M
- Latest round: Series D (Mar 26, 2014)
- Investors on record: 9

## About

Founded in 2007, Kolltan Pharmaceuticals, Inc. develops monoclonal antibody oncology therapeutics for the treatment of cancer and other diseases.

## Funding rounds

- Series D, Mar 26, 2014, $60M — HBM Partners, OUP (Osage University Partners), Fidelity Investments, Purdue Pharma, Elm Street Ventures, Deerfield Management, KLP Enterprises
- Series C, Mar 7, 2012, $25M — HBM Partners
- Series B, Sep 16, 2010, $3.5M — Auven Therapeutics
- Series B, Jan 4, 2010, $2.5M — Auven Therapeutics, Tichenor Ventures
- Series A, Aug 12, 2009, $40M — HBM Partners, Purdue Pharma

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A, Series C, Series D
- Purdue Pharma — Series A, Series D
- Auven Therapeutics (https://capitalatlas.ai/funds/auven-therapeutics) — Series B
- Tichenor Ventures — Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series D
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series D
- Elm Street Ventures (https://capitalatlas.ai/funds/elm-street-ventures) — Series D
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series D
- KLP Enterprises — Series D